Diasorin’s Liaison Nes Cleared: 510(k) and CLIA waiver for four‑plex

The US Food and Drug Administration issued 510(k) clearance and a CLIA waiver for Diasorin’s LIAISON Nes four‑plex molecular assay, enabling point‑of‑care PCR testing for influenza A/B, RSV and SARS‑CoV‑2. Diasorin says the Liaison Nes platform, developed with a major US pharmacy chain partner, produces lab‑quality results in roughly 15 minutes via a three‑step workflow. The company framed the clearance as its formal entry into the molecular POC market and said additional assays are planned for the platform. Point‑of‑care molecular PCR delivers laboratory‑level nucleic acid detection near patients, reducing time to actionable results compared with centralized labs.